Benitec Biopharma Inc (BNTC)

Benitec Biopharma's stock has been impacted by several events over the past six months. In November 2025, the company announced concurrent offerings, selling shares in underwritten and registered direct deals, raising approximately $100 million. Equity awards were granted to the CEO and a director in November 2025 and January 2026, respectively. Positive interim Phase 1b/2a results for high-dose BB-301 were announced in March 2026, leading to a stock price increase. Share dilution was identified as a minor risk in May 2026, with total shares outstanding growing by 34.1%. The stock experienced fluctuations in April-May 2026, with a decline in 8 out of 10 days, but gained on May 4 and May 8, 2026. As of May 1, 2026, the share price was $11.95, a 20.60% decline from May 2, 2025.

Benitec Biopharma's products and services do not exhibit traditional demand seasonality, as they focus on genetic medicines for chronic and life-threatening diseases. Demand is driven by medical need and clinical efficacy rather than seasonal factors. The company's revenue is not currently generated from product sales, but from funding and investments to support its research and development pipeline.

Benitec Biopharma, Inc. is a clinical-stage biotechnology company focused on advancing genetic medicines, operating in the Healthcare sector and Biotechnology industry. Their core technology, the ddRNAi platform, combines RNA interference with gene therapy to silence disease-causing genes and deliver replacement genes. Their major product in development is BB-301, an AAV-based gene therapy for OPMD, focusing on orphan diseases to leverage regulatory incentives.

Benitec Biopharma Inc. is headquartered in Hayward, California, and was founded in Australia in 1995 before listing on the NASDAQ. The EMA has granted Orphan Drug Designation for BB-301, indicating potential European market reach. The company's operational footprint is focused on research and development activities, with BB-301 undergoing clinical trials.

Benitec Biopharma's brand reputation has been positively influenced by key events related to BB-301. Encouraging interim data from the Phase 1b/2a clinical trial for OPMD suggests the "Silence and Replace" mechanism is functioning as intended. Positive interim clinical results for both low and high dose BB-301 were announced in March 2026, demonstrating continued durable improvements. BB-301 has received Orphan Drug Designation from the EMA and Orphan Drug and Fast Track Designations from the FDA. No specific negative events significantly impacted Benitec Biopharma's reputation in the past year.

Benitec Biopharma Inc. has 75 institutional owners and shareholders who have filed 13D/G or 13F forms with the SEC, holding a total of 32,169,771 shares. Major institutional shareholders include Suvretta Capital Management, LLC, Janus Henderson Group Plc, Franklin Resources Inc, Adage Capital Partners Gp, L.l.c., Ra Capital Management, L.p., Vanguard Group Inc, Nantahala Capital Management, LLC, BlackRock, Inc., Infinitum Asset Management, Llc and Siren, L.L.C.. Specific major individual owners holding over 5% were not explicitly detailed beyond the institutional filings.